Zenarestat
![]() | |
| Names | |
|---|---|
| IUPAC name
2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid | |
| Identifiers | |
| 112733-06-9 | |
| 3D model (Jmol) | Interactive image |
| ChemSpider | 5522 |
| 7418 | |
| KEGG | D03807 |
| PubChem | 5724 |
| |
| |
| Properties | |
| C17H11BrClFN2O4 | |
| Molar mass | 441.64 g/mol |
| Melting point | 223 to 224 °C (433 to 435 °F; 496 to 497 K) |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Zenarestat (FK-366; FR-74366) is an aldose reductase inhibitor. It was investigated as a treatment of diabetic neuropathy and cataract, but its development was terminated.[1]
References
- M. Hashimoto et al., EP 218999; eidem, US 4734419 (1987, 1988 both to Fujisawa)
- Inhibition kinetics and effect on sorbitol accumulation: S. Ao et al., Metabolism 40, 77 (1991)
- Pharmacokinetics and metabolism in diabetic rats: Y. Tanaka et al., Drug Metab. Dispos. 21, 677 (1993)
- M. Kanamaru et al., J. Clin. Pharmacol. 33, 1122 (1993).
- ↑ "Zenarestat — AdisInsight". Adis Insight. Springer International Publishing AG. Retrieved 3 January 2016.
This article is issued from Wikipedia - version of the 1/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
